Extract
Portopulmonary hypertension (PoPH) is a subtype of pulmonary arterial hypertension (PAH) complicating the course of portal hypertension [1, 2]. Similar to other causes of PAH, PoPH is characterised by a progressive structural and functional remodelling of small pulmonary arteries leading to pre-capillary pulmonary hypertension defined by a mean pulmonary artery pressure (mPAP) ≥25 mmHg, normal pulmonary artery wedge pressure (PAWP) ≤15 mmHg and raised pulmonary vascular resistance (PVR) >3 Wood Units (WU) [1]. PoPH negatively impacts survival of patients with portal hypertension. Early detection of PoPH is of particular importance because it is treatable with PAH drugs and basic therapies such as diuretics [1, 3].
Abstract
Pulmonary vascular resistance between 2 and 3 Wood Units in patients with portal hypertension and pre-capillary pulmonary hypertension could characterise early portopulmonary hypertension with clinical consequences https://bit.ly/3PEFe79
Acknowledgements
We thank all physicians from the French Pulmonary Hypertension Network (PulmoTension).
Footnotes
Conflict of interest: A. Boucly reports travel support and lecture honoraria from Janssen and MSD, outside the submitted work. X. Jaïs reports grants from Bayer, Janssen and Merck; lecture honoraria from Janssen and Merck; outside the submitted work. D. Montani reports grants from Acceleron, Janssen and Merck; consulting fees from Acceleron; lecture honoraria from Bayer, Janssen and Merck; outside the submitted work. M. Humbert reports grants and consulting fees from Acceleron, Janssen and Merck; lecture honoraria from Janssen and Merck; participation on advisory boards for Acceleron, Janssen, Merck and United Therapeutics; outside the submitted work. O. Sitbon reports grants from Acceleron, Janssen, GSK and MSD; consulting fees from Gossamer Bio, Janssen and MSD; lecture honoraria from AOP Orphan, Janssen, Ferrer and MSD; participation on advisory boards for Acceleron, Janssen and MSD; outside the submitted work. L. Savale reports grants from Janssen and Janssen, MSD and GSK; lecture honoraria from Janssen and Janssen and MSD; travel support from Janssen and Janssen; outside the submitted work. All other authors have nothing to disclose.
- Received January 16, 2022.
- Accepted May 22, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org